ArticleFrontiers in pharmacology2026
Pharmacoepidemiology of antipsychotic utilization among children and adolescents in Montevideo between 2018 and 2022.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prescription of antipsychotics in the pediatric population has increased worldwide, especially of second generation antipsychotics. Prescription patterns are not homogeneous across populations. Studies demonstrate differences according to sex, age and socioeconomic level. In Uruguay, the available evidence is limited and comes from small, single-center studies and does not provide information on changes over time. Purpose: describe the use of antipsychotics in 1- to 19-year-old children and adolescents in Montevideo between 2018 and 2022, considering differences according to socioeconomic level. Study design: A descriptive observational study of medication use was conducted. Methods: It included children and adolescent users of antipsychotics treated in eight healthcare centers in Montevideo (one public, five collective healthcare institutions, and two private insurance schemes), which together provide coverage to approximately 230,000 children and adolescents in total. Pharmacy dispensing data were analyzed between 1/1/2018 and 12/31/2022. The primary endpoint was the defined daily dose (DDD) per 1,000 inhabitants/day (DDD per 1,000 inhabitants/day), calculated globally and by drug. Temporal variation was evaluated in three periods: pre-pandemic (2018-2019), start of the pandemic (2020) and post-pandemic (2021-2022). Descriptive statistics were used. Findings: The average DDD per 1,000 inhabitants/day in the period was 11.4, with a predominance of risperidone and aripiprazole. The highest utilization was observed among adolescents aged 15-19 years, followed by the group aged 5-14 years, and was higher in males. Although the use of antipsychotics increased over time in all socioeconomic levels, it was higher for providers of care at the low socioeconomic level and lower for providers of care at the high socioeconomic level. Conclusion: This is the first study in Uruguay that describes the use of antipsychotic agents in children and adolescents by socioeconomic level; it showed a steady increase in their use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.